


PHARMACEUTICAL 2019

LIFECORE BIOMEDICAL INC. \DE\ Rank 111 of 363





LANDEC



PHARMACEUTICAL 2019

LIFECORE BIOMEDICAL INC. \DE Rank 111 of 363

The relative strengths and weaknesses of LIFECORE BIOMEDICAL INC. \DE\ are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIFECORE BIOMEDICAL INC. \DE\ compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 147% points. The greatest weakness of LIFECORE BIOMEDICAL INC. \DE\ is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 165%, being 128% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 97,063 |
| Cost of Goods Sold | 445,889 |
| Intangible Assets | 54,510 |
| Liabilities, Current | 88,375 |
| Liabilities, Non-Current | 37,360 |
| Other Assets | 93,506 |
| Other Compr. Net Income | 622 |
| Other Expenses | -7,413 |
| Other Liabilities | 26,406 |
| Other Net Income | 3,923 |
| Other Revenues | 524,227 |
| Property and Equipment | 159,624 |
| Research and Development | 12,800 |
| Selling, General and Administrative Expense | 51,951 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 404,703 |
| Liabilities | 152,141 |
| Expenses | 503,227 |
| Revenues | 524,227 |
| Stockholders Equity | 252,562 |
| Net Income | 24,923 |
| Comprehensive Net Income | 25,234 |
| Economic Capital Ratio | 165% |

LANDEC

